zambia herald : Latest News and In-depth Analysis

Opinion

Elcogen Applauded by Frost & Sullivan for Enabling High-efficiency, Emission-free Power and Green Hydrogen Production with Its Versatile Solid Oxide Fuel Cell and Stack Technologies

Elcogen\'s advanced SOFC and SOEC technologies provide scalable,cost-effective solutions for both residential and industrial applications that enable high efficiency,fuel flexibility,and lower emissi

Jan 15, 2025 Opinion

ITALY, SIGEP WORLD, THE GLOBAL FOODSERVICE COMMUNITY'S LEADING SHOW, IS ABOUT TO START: 1,300 BRANDS

Trends,innovation,technologies and now also pizza at Italian Exhibition Group\'s 46th edition featuring sustainable sector initiatives in the name of internationality,at Rimini Expo Centre from 18th

Jan 15, 2025 Opinion

GenScript upgrades product packaging with a recyclable strategy, reducing waste by 82% and contributing to environmental sustainability

PISCATAWAY,N.J.,Jan. 14,2025-- GenScript Biotech Corporation has unveiled an innovation in shipping packaging,propelling GenScript towards achieving their ambitious sustainability goals. The new packa

Jan 15, 2025 Opinion

Scientific Anti-Aging and Aesthetic Innovation: 180 the concept "Aesthetic Renaissance" Annual Gala Opens in Beijing

BEIJING,Jan. 14,2025-- OnJanuary 9,Spanish premiumnutri-cosmetics brand 180 the concept held its "Aesthetic Renaissance" Annual Gala in Partnering with Harper\'s BAZAAR and Harper\'s BAZAAR

Jan 15, 2025 Opinion

LEGO® Education Announces Hands-on Learning Solution for K-8 Science

Hands-on learning helps build confidence,yet only half of students have access to these experiences in science class,according to a new LEGO® Education report. LEGO® Education Science aims to

Jan 15, 2025 Opinion

ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS

SEOUL,South Korea,Jan. 14,2025-- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for \'Pemziviptadil (development code name PF1804),\' a treatment for DMD (Duch

Jan 15, 2025 Opinion
1 ... 93 94 95 96 97 98 99 ... 104